Double‐blind, placebo‐controlled multicenter trial using chimeric monoclonal anti‐cd4 antibody, cm‐t412, in rheumatoid arthritis patients receiving concomitant methotrexate

Larry W. Moreland, Parks W. Pratt, Maureen D. Mayes, Arnold Postlethwaite, Michael H. Weisman, Thomas Schnitzer, Robert Lightfoot, Leonard Calabrese, David J. Zelinger, James N. Woody, William J. Koopman

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Objective. To evaluate the clinical response to and safety of single and repeat doses of a chimeric anti‐CD4 monoclonal antibody, cM‐T412, in patients with rheumatoid arthritis (RA) concomitantly treated with a stable regimen of low‐dose methotrexate. Methods. Sixty‐four patients with refractory RA, who were already receiving stable doses of methotrexate, were randomized into a multicenter, double‐blind, placebo‐controlled trial to receive 3 monthly treatments with either a placebo, or 5, 10, or 50 mg cM‐T412, given intravenously. Results. Using ≥50% improvement in swollen joint counts as a criterion for clinical response, 13%, 13%, 18%, and 13% of patients receiving 50, 10, or 5 mg cM‐T412, or the placebo, respectively, exhibited a clinical response at 3 months of therapy. Using ≥50% improvement in tender joint counts as a measure of clinical efficacy at 3 months, 19%, 13%, 12%, and 6% of patients receiving 50, 10, or 5 mg cM‐T412, or the placebo, respectively, exhibited a clinical response. “Flu‐like” symptoms (fever, chills, rigor) within 24 hours of the infusion occurred more frequently in the groups receiving 50‐mg (29%) and 10‐mg (31%) doses of cM‐T412 than those receiving 5 mg cM‐T412 (12%) or the placebo (13%). Significant CD4+ T cell depletion occurred in the 50‐mg group (mean of 353 CD4+ T cells/mm3 at 6 months versus 856 CD4+ T cells/mm3 at baseline). All patients were followed up for 12 months after the final treatment; no opportunistic infectious complications occurred. Conclusion. Treatment with cM‐T412 in this cohort of RA patients who were also taking methotrexate was not associated with clinical efficacy or enhanced toxicity from infectious complications, despite significant peripheral CD4+ T cell depletion.

Original languageEnglish (US)
Pages (from-to)1581-1588
Number of pages8
JournalArthritis & Rheumatism
Volume38
Issue number11
DOIs
StatePublished - Jan 1 1995

Fingerprint

Methotrexate
Multicenter Studies
Rheumatoid Arthritis
Monoclonal Antibodies
Placebos
T-Lymphocytes
Joints
Chills
Therapeutics
Fever
Safety

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Double‐blind, placebo‐controlled multicenter trial using chimeric monoclonal anti‐cd4 antibody, cm‐t412, in rheumatoid arthritis patients receiving concomitant methotrexate. / Moreland, Larry W.; Pratt, Parks W.; Mayes, Maureen D.; Postlethwaite, Arnold; Weisman, Michael H.; Schnitzer, Thomas; Lightfoot, Robert; Calabrese, Leonard; Zelinger, David J.; Woody, James N.; Koopman, William J.

In: Arthritis & Rheumatism, Vol. 38, No. 11, 01.01.1995, p. 1581-1588.

Research output: Contribution to journalArticle

Moreland, LW, Pratt, PW, Mayes, MD, Postlethwaite, A, Weisman, MH, Schnitzer, T, Lightfoot, R, Calabrese, L, Zelinger, DJ, Woody, JN & Koopman, WJ 1995, 'Double‐blind, placebo‐controlled multicenter trial using chimeric monoclonal anti‐cd4 antibody, cm‐t412, in rheumatoid arthritis patients receiving concomitant methotrexate', Arthritis & Rheumatism, vol. 38, no. 11, pp. 1581-1588. https://doi.org/10.1002/art.1780381109
Moreland, Larry W. ; Pratt, Parks W. ; Mayes, Maureen D. ; Postlethwaite, Arnold ; Weisman, Michael H. ; Schnitzer, Thomas ; Lightfoot, Robert ; Calabrese, Leonard ; Zelinger, David J. ; Woody, James N. ; Koopman, William J. / Double‐blind, placebo‐controlled multicenter trial using chimeric monoclonal anti‐cd4 antibody, cm‐t412, in rheumatoid arthritis patients receiving concomitant methotrexate. In: Arthritis & Rheumatism. 1995 ; Vol. 38, No. 11. pp. 1581-1588.
@article{79506927037c40a9862912d3bdec329d,
title = "Double‐blind, placebo‐controlled multicenter trial using chimeric monoclonal anti‐cd4 antibody, cm‐t412, in rheumatoid arthritis patients receiving concomitant methotrexate",
abstract = "Objective. To evaluate the clinical response to and safety of single and repeat doses of a chimeric anti‐CD4 monoclonal antibody, cM‐T412, in patients with rheumatoid arthritis (RA) concomitantly treated with a stable regimen of low‐dose methotrexate. Methods. Sixty‐four patients with refractory RA, who were already receiving stable doses of methotrexate, were randomized into a multicenter, double‐blind, placebo‐controlled trial to receive 3 monthly treatments with either a placebo, or 5, 10, or 50 mg cM‐T412, given intravenously. Results. Using ≥50{\%} improvement in swollen joint counts as a criterion for clinical response, 13{\%}, 13{\%}, 18{\%}, and 13{\%} of patients receiving 50, 10, or 5 mg cM‐T412, or the placebo, respectively, exhibited a clinical response at 3 months of therapy. Using ≥50{\%} improvement in tender joint counts as a measure of clinical efficacy at 3 months, 19{\%}, 13{\%}, 12{\%}, and 6{\%} of patients receiving 50, 10, or 5 mg cM‐T412, or the placebo, respectively, exhibited a clinical response. “Flu‐like” symptoms (fever, chills, rigor) within 24 hours of the infusion occurred more frequently in the groups receiving 50‐mg (29{\%}) and 10‐mg (31{\%}) doses of cM‐T412 than those receiving 5 mg cM‐T412 (12{\%}) or the placebo (13{\%}). Significant CD4+ T cell depletion occurred in the 50‐mg group (mean of 353 CD4+ T cells/mm3 at 6 months versus 856 CD4+ T cells/mm3 at baseline). All patients were followed up for 12 months after the final treatment; no opportunistic infectious complications occurred. Conclusion. Treatment with cM‐T412 in this cohort of RA patients who were also taking methotrexate was not associated with clinical efficacy or enhanced toxicity from infectious complications, despite significant peripheral CD4+ T cell depletion.",
author = "Moreland, {Larry W.} and Pratt, {Parks W.} and Mayes, {Maureen D.} and Arnold Postlethwaite and Weisman, {Michael H.} and Thomas Schnitzer and Robert Lightfoot and Leonard Calabrese and Zelinger, {David J.} and Woody, {James N.} and Koopman, {William J.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1002/art.1780381109",
language = "English (US)",
volume = "38",
pages = "1581--1588",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Double‐blind, placebo‐controlled multicenter trial using chimeric monoclonal anti‐cd4 antibody, cm‐t412, in rheumatoid arthritis patients receiving concomitant methotrexate

AU - Moreland, Larry W.

AU - Pratt, Parks W.

AU - Mayes, Maureen D.

AU - Postlethwaite, Arnold

AU - Weisman, Michael H.

AU - Schnitzer, Thomas

AU - Lightfoot, Robert

AU - Calabrese, Leonard

AU - Zelinger, David J.

AU - Woody, James N.

AU - Koopman, William J.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Objective. To evaluate the clinical response to and safety of single and repeat doses of a chimeric anti‐CD4 monoclonal antibody, cM‐T412, in patients with rheumatoid arthritis (RA) concomitantly treated with a stable regimen of low‐dose methotrexate. Methods. Sixty‐four patients with refractory RA, who were already receiving stable doses of methotrexate, were randomized into a multicenter, double‐blind, placebo‐controlled trial to receive 3 monthly treatments with either a placebo, or 5, 10, or 50 mg cM‐T412, given intravenously. Results. Using ≥50% improvement in swollen joint counts as a criterion for clinical response, 13%, 13%, 18%, and 13% of patients receiving 50, 10, or 5 mg cM‐T412, or the placebo, respectively, exhibited a clinical response at 3 months of therapy. Using ≥50% improvement in tender joint counts as a measure of clinical efficacy at 3 months, 19%, 13%, 12%, and 6% of patients receiving 50, 10, or 5 mg cM‐T412, or the placebo, respectively, exhibited a clinical response. “Flu‐like” symptoms (fever, chills, rigor) within 24 hours of the infusion occurred more frequently in the groups receiving 50‐mg (29%) and 10‐mg (31%) doses of cM‐T412 than those receiving 5 mg cM‐T412 (12%) or the placebo (13%). Significant CD4+ T cell depletion occurred in the 50‐mg group (mean of 353 CD4+ T cells/mm3 at 6 months versus 856 CD4+ T cells/mm3 at baseline). All patients were followed up for 12 months after the final treatment; no opportunistic infectious complications occurred. Conclusion. Treatment with cM‐T412 in this cohort of RA patients who were also taking methotrexate was not associated with clinical efficacy or enhanced toxicity from infectious complications, despite significant peripheral CD4+ T cell depletion.

AB - Objective. To evaluate the clinical response to and safety of single and repeat doses of a chimeric anti‐CD4 monoclonal antibody, cM‐T412, in patients with rheumatoid arthritis (RA) concomitantly treated with a stable regimen of low‐dose methotrexate. Methods. Sixty‐four patients with refractory RA, who were already receiving stable doses of methotrexate, were randomized into a multicenter, double‐blind, placebo‐controlled trial to receive 3 monthly treatments with either a placebo, or 5, 10, or 50 mg cM‐T412, given intravenously. Results. Using ≥50% improvement in swollen joint counts as a criterion for clinical response, 13%, 13%, 18%, and 13% of patients receiving 50, 10, or 5 mg cM‐T412, or the placebo, respectively, exhibited a clinical response at 3 months of therapy. Using ≥50% improvement in tender joint counts as a measure of clinical efficacy at 3 months, 19%, 13%, 12%, and 6% of patients receiving 50, 10, or 5 mg cM‐T412, or the placebo, respectively, exhibited a clinical response. “Flu‐like” symptoms (fever, chills, rigor) within 24 hours of the infusion occurred more frequently in the groups receiving 50‐mg (29%) and 10‐mg (31%) doses of cM‐T412 than those receiving 5 mg cM‐T412 (12%) or the placebo (13%). Significant CD4+ T cell depletion occurred in the 50‐mg group (mean of 353 CD4+ T cells/mm3 at 6 months versus 856 CD4+ T cells/mm3 at baseline). All patients were followed up for 12 months after the final treatment; no opportunistic infectious complications occurred. Conclusion. Treatment with cM‐T412 in this cohort of RA patients who were also taking methotrexate was not associated with clinical efficacy or enhanced toxicity from infectious complications, despite significant peripheral CD4+ T cell depletion.

UR - http://www.scopus.com/inward/record.url?scp=0028882681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028882681&partnerID=8YFLogxK

U2 - 10.1002/art.1780381109

DO - 10.1002/art.1780381109

M3 - Article

VL - 38

SP - 1581

EP - 1588

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 11

ER -